Literature DB >> 30244051

Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study).

Alper Sonmez1, Cem Haymana2, Fahri Bayram3, Serpil Salman4, Oguzhan Sitki Dizdar5, Eren Gurkan6, Ayse Kargili Carlıoglu7, Cem Barcin8, Tevfik Sabuncu9, Ilhan Satman10.   

Abstract

AIMS: Turkey has the highest prevalence of diabetes in Europe. It is therefore essential to know the overall cardiovascular risk and reveal the predictors of metabolic control in Turkish adults with diabetes mellitus.
METHODS: A nationwide, multicenter survey consecutively enrolled patients who were under follow up for at least a year. Optimal control was defined as HbA1c < 7%, home arterial blood pressure (ABP) < 135/85 mmHg, or LDL-C < 100 mg/dL. Achieving all parameters indicated triple metabolic control.
RESULTS: HbA1c levels of patients (n = 5211) were 8.6 ± 1.9% (71 ± 22 mmol/mol) and 7.7 ± 1.7% (61 ± 19 mmol/mol), in Type 1 and Type 2 diabetes, respectively. Glycemic control was achieved in 15.3% and 40.2%, and triple metabolic control was achieved in 5.5% and 10.1%, respectively. Only 1.5% of patients met all the criteria of being non-obese, non-smoker, exercising, and under triple metabolic control. Low education level was a significant predictor of poor glycemic control in both groups.
CONCLUSIONS: Few patients with Type 2, and even fewer with Type 1 diabetes have optimal metabolic control in Turkey. TEMD study will provide evidence-based information to policy makers to focus more on the quality and sustainability of diabetes care in order to reduce the national burden of the disease.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Arterial blood pressure; HbA1c; LDL-cholesterol; Type 1 diabetes; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30244051     DOI: 10.1016/j.diabres.2018.09.010

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  9 in total

1.  EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE.

Authors:  H G Gunhan; E Imre; P Erel; O Ustay
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

2.  Characteristics and Treatment Patterns of Patients with Type 2 Diabetes Mellitus in the Middle East and Africa Cohort of the DISCOVER Study Program: a Prospective Study.

Authors:  Khalid Al-Rubeaan; Mohamed Alsayed; Abdullah Ben-Nakhi; Fahri Bayram; Akram Echtay; Ahmed Hadaoui; Khadija Hafidh; Kevin Kennedy; Adri Kok; Rachid Malek; Viraj Rajadhyaksha; Suzanne V Arnold
Journal:  Diabetes Ther       Date:  2022-06-11       Impact factor: 3.595

3.  Impact of Obesity on the Metabolic Control of Type 2 Diabetes: Results of the Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD Obesity Study).

Authors:  Alper Sonmez; Volkan Yumuk; Cem Haymana; Ibrahim Demirci; Cem Barcin; Sinem Kıyıcı; Sibel Güldiken; Gonca Örük; Basak Ozgen Saydam; Süleyman Baldane; Faruk Kutlutürk; Ferit Kerim Küçükler; Oğuzhan Deyneli; Berrin Çetinarslan; Tevfik Sabuncu; Fahri Bayram; Ilhan Satman
Journal:  Obes Facts       Date:  2019-03-20       Impact factor: 4.807

4.  Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia).

Authors:  Alper Sonmez; Ibrahim Demirci; Cem Haymana; Ilker Tasci; Selcuk Dagdelen; Serpil Salman; Naim Ata; Ibrahim Sahin; Rifat Emral; Erman Cakal; Aysegul Atmaca; Mustafa Sahin; Osman Celik; Tevfik Demir; Derun Ertugrul; Ugur Unluturk; Murat Caglayan; Ilhan Satman
Journal:  J Diabetes       Date:  2021-03-24       Impact factor: 4.530

5.  The Compatibility of the Treatment Modalities to the Recommendations of the Kidney Disease Outcomes Quality Initiative Guideline in Chronic Kidney Disease Patients with Diabetes.

Authors:  Zelal Adibelli; Cevdet Duran
Journal:  Iran J Public Health       Date:  2021-06       Impact factor: 1.429

Review 6.  Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.

Authors:  Alper Sonmez; Hani Sabbour; Akram Echtay; Abbas Mahdi Rahmah; Amani Matook Alhozali; Fahad Sulman Al Sabaan; Fares H Haddad; Hinde Iraqi; Ibrahim Elebrashy; Samir N Assaad; Zaheer Bayat; Zeynep Osar Siva; Mohamed Hassanein
Journal:  J Diabetes       Date:  2022-04-17       Impact factor: 4.530

7.  Glycemic control and its influencing factors in type 2 diabetes patients in Anhui, China.

Authors:  Xiu-Ya Xing; Xin-Yi Wang; Xi Fang; Jing-Qiao Xu; Ye-Ji Chen; Wei Xu; Hua-Dong Wang; Zhi-Rong Liu; Sha-Sha Tao
Journal:  Front Public Health       Date:  2022-10-04

8.  Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).

Authors:  Fahri Bayram; Alper Sonmez; Cem Haymana; Tevfik Sabuncu; Oguzhan Sitki Dizdar; Eren Gurkan; Ayse Kargili Carlioglu; Kemal Agbaht; Didem Ozdemir; Ibrahim Demirci; Cem Barcin; Serpil Salman; Tamer Tetiker; Mustafa Kemal Balci; Nur Kebapci; Canan Ersoy; Volkan Yumuk; Peter P Toth; Ilhan Satman
Journal:  Lipids Health Dis       Date:  2020-11-11       Impact factor: 3.876

9.  Rates and associates of influenza and pneumococcus vaccination in diabetes mellitus: A nationwide cross-sectional study (TEMD vaccination study).

Authors:  Ibrahim Demirci; Cem Haymana; Serpil Salman; Ilker Tasci; Demet Corapcioglu; Ali Kirik; İlhan Yetkin; Mustafa Altay; Tevfik Sabuncu; Fahri Bayram; Ilhan Satman; Alper Sonmez
Journal:  World J Diabetes       Date:  2021-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.